Emotra AB (“Emotra”) has had an eventful spring. New data which show that EDOR® can identify patients with an increased risk of depressive relapse are turning out to be more and more important. Emotra is now increasingly engaged in discussions with psychiatric research centres concerning collaborations to verify these findings and identify new application areas [...]
The Annual General Meeting of EMOTRA AB (publ) was held today, May 15, 2019. The resolutions, summarised below, were all adopted with the necessary majority. 190515 - Emotra- PM - Communiqué from AGM
The Board and CEO of Emotra AB (publ) hereby present the interim report for the first quarter 2019. 190515 Interim report Jan-March 2019
Emotra has previously announced that new research results have indicated new application areas for Emotra’s method, EDOR. These areas open new possibilities for widening the method’s use in clinical practice. We can now reveal that the application in question concerns the fact that hyporeactive patients run a higher risk of depression relapse than normally reactive [...]
The US will be one of Emotra’s priority markets in the future. We have earlier announced that the Company has applied for patents in the EU, USA, Canada and Japan and patents have been granted in Sweden and Japan. The US patent office has now informed us that Emotra’s American patent application “US Application No. [...]
Emotra AB (publ) (“Emotra”) today announces that the Company’s Annual Report for the financial year 2018, as well as other documents required for the Annual General Meeting are available from the Company’s web site (www.emotra.se) as of today, and are also provided upon request by the Company (see address below). 190424 - Emotra- PM [...]
Notice is hereby given that the Annual General Meeting of shareholders in Emotra AB (publ), 556612-1579, will be held at 11:00 am on Wednesday May 15, 2019, at the restaurant John Scott´s Pub at 15, Kungsportsavenyn in Göteborg, Sweden. 190415 - Emotra- PM - Notice AGM
Emotra has learnt that communications from an individual researcher have been disclosed to the financial market. Yesterday and this evening, Emotra has been receiving questions from concerned shareholders about our open, naturalistic, multi-centre study, EUDOR-A. We therefore intend to address this situation through this press release. 190305 - Emotra - PM - Comments on [...]
The Board and CEO of Emotra AB herewith present the year-end report for the financial year 2018. 190221- Year-end report 2018
Emotra AB (“Emotra”) is proud to announce that researchers have demonstrated a further application area for Emotra’s method EDOR®. Researchers at a psychiatric clinic have made a discovery that shows a possible further application of EDOR Test in clinical practice. Their results correlate with recent findings on the biological mechanism behind hyporeactivity. 190205 - [...]